IC
VRDN icon

Ikarian Capital’s Viridian Therapeutics VRDN Stock Holding History

Ikarian Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,789
Closed -$3.63M – 172
2024
Q2 		$3.63M Sell
2,789
-176,111
-98% -$2.44M 0.63% 38
2024
Q1 		$3.13M Buy
+178,900
New +$3.47M 0.34% 68

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Ikarian Capital's VRDN Position: Q4 2025 in Review

Ikarian Capital sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 245,518 shares — an estimated $5.3M sold.

Ikarian Capital first reported a position in VRDN in Q3 2024 and held it in 5 quarters. The position peaked at $11.4M in Q3 2024. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Ikarian Capital reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 245,518 Viridian Therapeutics shares in Q4 2025, an estimated $5.3M.
  • Ikarian Capital first reported a position in Viridian Therapeutics in Q3 2024 and held it in 5 quarters.
  • Ikarian Capital's Viridian Therapeutics position peaked at $11.4M in Q3 2024.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.